Nederlands tijdschrift voor geneeskunde · 1993
[Ranitidine therapeutically effective in functional dyspepsia with reflux-like symptoms].
Клиническое исследованиеАннотация на английскомСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jebbink H J, Smout A J, van Berge Henegouwen G P
Аннотация
OBJECTIVE: To investigate the effect of ranitidine in patients with functional dyspepsia according to different subgroups.
SETTING: University Hospital Utrecht, department of gastroenterology.
DESIGN: Prospective double blind cross-over study.
METHOD: Thirty patients with chronic upper abdominal symptoms were included, without somatic cause was found at gastroscopy (no Helicobacter pylori), ultrasonography and blood tests. The mean symptom score of: nausea, vomiting, retrosternal pain, epigastric pain, heartburn, bloating, belching, and early satiety was > or = 2. The patients recorded severity and frequency of the symptoms in a diary. The same diary was used to score the symptoms during treatment with ranitidine (2 dd 150 mg) or placebo, each for 2 weeks with a wash out period of 3 days. 29 patients scored correctly.
RESULTS: 13 (43%) patients had dysmotility-like dyspepsia, 5 (17%) reflux-like dyspepsia, and 11 (40%) non-specific dyspepsia (i.e. a combination of dysmotility-like, reflux-like or ulcer-like symptoms). Ranitidine significantly improved the severity of heartburn after two weeks of treatment, as compared to placebo (p = 0.035), notably in the patients with reflux-like dyspepsia. Because of a carry-over effect analysis of the symptoms 'belching' and 'early satiety' was not possible.
CONCLUSION: Within the group of patients with functional dyspepsia a subgroup of reflux-like dyspepsia patients can be identified that responds well to ranitidine.
SETTING: University Hospital Utrecht, department of gastroenterology.
DESIGN: Prospective double blind cross-over study.
METHOD: Thirty patients with chronic upper abdominal symptoms were included, without somatic cause was found at gastroscopy (no Helicobacter pylori), ultrasonography and blood tests. The mean symptom score of: nausea, vomiting, retrosternal pain, epigastric pain, heartburn, bloating, belching, and early satiety was > or = 2. The patients recorded severity and frequency of the symptoms in a diary. The same diary was used to score the symptoms during treatment with ranitidine (2 dd 150 mg) or placebo, each for 2 weeks with a wash out period of 3 days. 29 patients scored correctly.
RESULTS: 13 (43%) patients had dysmotility-like dyspepsia, 5 (17%) reflux-like dyspepsia, and 11 (40%) non-specific dyspepsia (i.e. a combination of dysmotility-like, reflux-like or ulcer-like symptoms). Ranitidine significantly improved the severity of heartburn after two weeks of treatment, as compared to placebo (p = 0.035), notably in the patients with reflux-like dyspepsia. Because of a carry-over effect analysis of the symptoms 'belching' and 'early satiety' was not possible.
CONCLUSION: Within the group of patients with functional dyspepsia a subgroup of reflux-like dyspepsia patients can be identified that responds well to ranitidine.